HAVN Life Sciences Inc.
HAVN
CNSX
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -513.10K | 188.00K | -3.03M | -8.97M | -1.73M |
| Total Depreciation and Amortization | 100.00 | -17.60K | 35.40K | 130.50K | 104.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.60K | -724.10K | 2.20M | 7.86M | 456.00K |
| Change in Net Operating Assets | 602.90K | 134.40K | 103.70K | -161.80K | 26.00K |
| Cash from Operations | 214.50K | -419.30K | -692.20K | -1.14M | -1.14M |
| Capital Expenditure | -- | -- | -- | 0.00 | -13.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 22.10K | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Investing | -- | -- | -- | 22.10K | -13.40K |
| Total Debt Issued | -283.80K | 421.50K | -- | -- | -- |
| Total Debt Repaid | -- | 32.70K | -32.70K | -32.70K | -32.70K |
| Issuance of Common Stock | -- | -- | -- | 2.00M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -20.00K | -334.70K | -- |
| Cash from Financing | -210.50K | 341.30K | -41.00K | 1.29M | -25.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.00K | -78.00K | -733.20K | 166.40K | -1.18M |